These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid. Gault VA; Hölscher C Eur J Pharmacol; 2008 Jun; 587(1-3):112-7. PubMed ID: 18466898 [TBL] [Abstract][Full Text] [Related]
24. [Gly(14)]-humanin rescues long-term potentiation from amyloid beta protein-induced impairment in the rat hippocampal CA1 region in vivo. Guo F; Jing W; Ma CG; Wu MN; Zhang JF; Li XY; Qi JS Synapse; 2010 Jan; 64(1):83-91. PubMed ID: 19768812 [TBL] [Abstract][Full Text] [Related]
25. Neuregulin-1 prevents amyloid β-induced impairment of long-term potentiation in hippocampal slices via ErbB4. Min SS; An J; Lee JH; Seol GH; Im JH; Kim HS; Baik TK; Woo RS Neurosci Lett; 2011 Nov; 505(1):6-9. PubMed ID: 21787838 [TBL] [Abstract][Full Text] [Related]
26. Insulin rescues amyloid beta-induced impairment of hippocampal long-term potentiation. Lee CC; Kuo YM; Huang CC; Hsu KS Neurobiol Aging; 2009 Mar; 30(3):377-87. PubMed ID: 17692997 [TBL] [Abstract][Full Text] [Related]
27. Impairment of hippocampal CA1 heterosynaptic transformation and spatial memory by beta-amyloid(25-35). Sun MK; Alkon DL J Neurophysiol; 2002 May; 87(5):2441-9. PubMed ID: 11976381 [TBL] [Abstract][Full Text] [Related]
28. Mechanisms of the inhibitory effects of amyloid beta-protein on synaptic plasticity. Rowan MJ; Klyubin I; Wang Q; Anwyl R Exp Gerontol; 2004; 39(11-12):1661-7. PubMed ID: 15582282 [TBL] [Abstract][Full Text] [Related]
29. Agonists of peroxisome proliferator-activated receptor-gamma attenuate the Abeta-mediated impairment of LTP in the hippocampus in vitro. Costello DA; O'Leary DM; Herron CE Neuropharmacology; 2005 Sep; 49(3):359-66. PubMed ID: 15993441 [TBL] [Abstract][Full Text] [Related]
30. Amyloid-beta at sublethal level impairs BDNF-induced arc expression in cortical neurons. Wang DC; Chen SS; Lee YC; Chen TJ Neurosci Lett; 2006 May; 398(1-2):78-82. PubMed ID: 16412575 [TBL] [Abstract][Full Text] [Related]
31. Synaptic plasticity in animal models of early Alzheimer's disease. Rowan MJ; Klyubin I; Cullen WK; Anwyl R Philos Trans R Soc Lond B Biol Sci; 2003 Apr; 358(1432):821-8. PubMed ID: 12740129 [TBL] [Abstract][Full Text] [Related]
33. Nicotine enhances the depressive actions of A beta 1-40 on long-term potentiation in the rat hippocampal CA1 region in vivo. Freir DB; Herron CE J Neurophysiol; 2003 Jun; 89(6):2917-22. PubMed ID: 12611941 [TBL] [Abstract][Full Text] [Related]
34. Chronic but not acute intracerebroventricular administration of amyloid beta-peptide(25-35) decreases somatostatin content, adenylate cyclase activity, somatostatin-induced inhibition of adenylate cyclase activity, and adenylate cyclase I levels in the rat hippocampus. Burgos-Ramos E; Hervás-Aguilar A; Puebla-Jiménez L; Boyano-Adánez MC; Arilla-Ferreiro E J Neurosci Res; 2007 Feb; 85(2):433-42. PubMed ID: 17086550 [TBL] [Abstract][Full Text] [Related]
35. Repetitive induction of late-phase LTP produces long-lasting synaptic enhancement accompanied by synaptogenesis in cultured hippocampal slices. Tominaga-Yoshino K; Urakubo T; Okada M; Matsuda H; Ogura A Hippocampus; 2008; 18(3):281-93. PubMed ID: 18058822 [TBL] [Abstract][Full Text] [Related]
36. Alpha v integrins mediate beta-amyloid induced inhibition of long-term potentiation. Wang Q; Klyubin I; Wright S; Griswold-Prenner I; Rowan MJ; Anwyl R Neurobiol Aging; 2008 Oct; 29(10):1485-93. PubMed ID: 17442458 [TBL] [Abstract][Full Text] [Related]
37. [Effects of amyloid β-protein on hippocampal long-term potentiation]. Zhang JF; Yang D; Qi JS Sheng Li Xue Bao; 2010 Dec; 62(6):479-88. PubMed ID: 21170492 [TBL] [Abstract][Full Text] [Related]
38. Soluble amyloid-beta peptides potently disrupt hippocampal synaptic plasticity in the absence of cerebrovascular dysfunction in vivo. Hu NW; Smith IM; Walsh DM; Rowan MJ Brain; 2008 Sep; 131(Pt 9):2414-24. PubMed ID: 18678563 [TBL] [Abstract][Full Text] [Related]
39. Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-beta oligomers. Townsend M; Cleary JP; Mehta T; Hofmeister J; Lesne S; O'Hare E; Walsh DM; Selkoe DJ Ann Neurol; 2006 Dec; 60(6):668-76. PubMed ID: 17192927 [TBL] [Abstract][Full Text] [Related]